Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D.
作者信息
Tseng Chien-Wen, Masuda Camlyn, Chen Randi, Hartung Daniel M
机构信息
Department of Family Medicine and Community Health, University of Hawai'i John A. Burns School of Medicine, Honolulu, HI
Daniel K. Inouye College of Pharmacy, University of Hawai'i at Hilo, Hilo, HI.
出版信息
Diabetes Care. 2020 Apr;43(4):e50-e51. doi: 10.2337/dc19-1294. Epub 2020 Feb 10.
Abstract
摘要
相似文献
1
Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D.
Diabetes Care. 2020 Apr;43(4):e50-e51. doi: 10.2337/dc19-1294. Epub 2020 Feb 10.
2
Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
Res Social Adm Pharm. 2020 Sep;16(9):1290-1293. doi: 10.1016/j.sapharm.2019.05.017. Epub 2019 May 24.
3
Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
JAMA Netw Open. 2020 Apr 1;3(4):e203969. doi: 10.1001/jamanetworkopen.2020.3969.
4
Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
JAMA Intern Med. 2021 Dec 1;181(12):1605-1611. doi: 10.1001/jamainternmed.2021.5997.
5
Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs.
Neurol Clin Pract. 2021 Aug;11(4):298-303. doi: 10.1212/CPJ.0000000000000929.
6
Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.
Urol Pract. 2023 Sep;10(5):476-483. doi: 10.1097/UPJ.0000000000000425. Epub 2023 Jul 3.
7
Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
JAMA Intern Med. 2019 Mar 1;179(3):374-380. doi: 10.1001/jamainternmed.2018.6417.
8
The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
Curr Cardiol Rep. 2023 Jun;25(6):577-581. doi: 10.1007/s11886-023-01878-7. Epub 2023 Apr 25.
9
The Rising Cost of Insulin for Pump Users: How Policy Drives Prices.
J Diabetes Sci Technol. 2021 Sep;15(5):1177-1180. doi: 10.1177/1932296820947100. Epub 2020 Aug 6.
10
Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.
JAMA Netw Open. 2020 Apr 1;3(4):e202739. doi: 10.1001/jamanetworkopen.2020.2739.
引用本文的文献
1
Filling Diabetes Medications Through VA or Medicare, or Both: Factors in Decision Making, Challenges, and Informational Needs.
J Gen Intern Med. 2025 May 6. doi: 10.1007/s11606-025-09576-6.
2
"Can I afford to live today?" The emotional toll of navigating the healthcare system with type 1 diabetes.
Front Endocrinol (Lausanne). 2025 Mar 24;16:1555265. doi: 10.3389/fendo.2025.1555265. eCollection 2025.
3
Health Outcome Changes in Individuals With Type 1 Diabetes After a State-Level Insulin Copayment Cap.
JAMA Netw Open. 2024 Aug 1;7(8):e2425280. doi: 10.1001/jamanetworkopen.2024.25280.
4
Exacerbation of financial burden of insulin and overall glucose-lowing medications among uninsured population with diabetes.
J Diabetes. 2023 Mar;15(3):215-223. doi: 10.1111/1753-0407.13360. Epub 2023 Feb 7.
5
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare.
Diabetes Care. 2022 Aug 1;45(8):1814-1821. doi: 10.2337/dc21-2601.
6
Cutaneous Manifestation of Diabetes Mellitus in an Unsheltered Male Leading to Emergent Hospitalization.
Cureus. 2022 Feb 21;14(2):e22432. doi: 10.7759/cureus.22432. eCollection 2022 Feb.
7
Development of a computerized intervention to improve health literacy in older Hispanics with type 2 diabetes using a pharmacist supervised comprehensive medication management.
PLoS One. 2022 Feb 9;17(2):e0263264. doi: 10.1371/journal.pone.0263264. eCollection 2022.
8
The impact of biosimilar insulins on the diabetes landscape.
J Manag Care Spec Pharm. 2022 Jan;28(1):91-98. doi: 10.18553/jmcp.2021.21253. Epub 2021 Nov 2.
9
Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs.
Neurol Clin Pract. 2021 Aug;11(4):298-303. doi: 10.1212/CPJ.0000000000000929.
10
High Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries With Diabetes, 1999-2017.
Diabetes Care. 2021 Aug;44(8):1797-1804. doi: 10.2337/dc20-2708. Epub 2021 Jun 28.
本文引用的文献
1
Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices.
N Engl J Med. 2019 Oct 10;381(15):1401-1404. doi: 10.1056/NEJMp1908688. Epub 2019 Sep 4.
2
Cost-Related Insulin Underuse Among Patients With Diabetes.
JAMA Intern Med. 2019 Jan 1;179(1):112-114. doi: 10.1001/jamainternmed.2018.5008.
3
Erratum. Insulin Access and Affordability Working Group: Conclusions and Recommendations. Diabetes Care 2018;41;1299-1311.
Diabetes Care. 2018 Aug;41(8):1831. doi: 10.2337/dc18-er08. Epub 2018 Jun 28.
Zotero 插件